William Blair analyst Matt Phipps has reiterated their bullish stance on GMAB stock, giving a Buy rating today.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matt Phipps has given his Buy rating due to a combination of factors tied to Genmab’s current data and future pipeline potential. Although the confirmatory Phase III EPCORE DLBCL-1 trial for Epkinly did not achieve statistical significance on overall survival, it did meet the progression-free survival endpoint, and he views the overall risk to the current accelerated approval in relapsed/refractory DLBCL as limited. He highlights that regulatory precedent, including the situation with a competing therapy that retains accelerated approval despite a negative confirmatory study, suggests Epkinly’s existing indication is unlikely to be withdrawn. He also notes that some of the overall survival outcome may have been affected by external elements such as COVID-19 and the availability of newer follow-on treatments, warranting a fuller data review once presented.
Phipps emphasizes that the more meaningful value driver lies in Genmab’s upcoming late-stage programs rather than the confirmatory DLBCL-1 result alone. He remains confident in the strong Phase II data for Epkinly combined with R-CHOP in frontline DLBCL, which underpins expectations for the pivotal EPCORE DLBCL-2 readout in 2026 and the opportunity to expand into the largest part of the DLBCL market. In addition, he points to a broader 2026 catalyst calendar, with multiple pivotal results anticipated not only for Epkinly but also for Rina-S and petosemtamab, which together could materially increase Genmab’s commercial footprint. Taken together, the durable strategic position in DLBCL, the low perceived risk to the current approval, and the substantial upside from several near- to midterm pivotal trials support his continued Outperform (Buy) recommendation on Genmab shares.
In another report released today, Truist Financial also maintained a Buy rating on the stock with a $48.00 price target.